vTv Therapeutics (NASDAQ:VTVT) Given Buy Rating at BTIG Research

by · The Markets Daily

vTv Therapeutics (NASDAQ:VTVT – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at BTIG Research in a note issued to investors on Wednesday, Benzinga reports. They presently have a $57.00 price target on the biotechnology company’s stock. BTIG Research’s target price indicates a potential upside of 102.09% from the company’s current price.

A number of other equities research analysts have also weighed in on VTVT. Zacks Research raised vTv Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Rodman & Renshaw initiated coverage on vTv Therapeutics in a report on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price target for the company. Lifesci Capital raised vTv Therapeutics to a “strong-buy” rating in a report on Wednesday, September 2nd. Wall Street Zen upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 3rd. Finally, Weiss Ratings lowered vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $55.83.

Read Our Latest Stock Report on vTv Therapeutics

vTv Therapeutics Stock Performance

Shares of vTv Therapeutics stock opened at $28.21 on Wednesday. vTv Therapeutics has a one year low of $19.50 and a one year high of $44.00. The company has a market cap of $111.13 million, a P/E ratio of -26.19 and a beta of 0.21. The firm has a fifty day moving average of $31.90 and a two-hundred day moving average of $33.55.

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.08). As a group, equities analysts predict that vTv Therapeutics will post -2.35 earnings per share for the current year.

About vTv Therapeutics

(Get Free Report)

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.

See Also